Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Standard
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. / Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Herzog, Christopher; Umutlu, Lale; Frydrychowicz, Alex; Rjosk-Dendorfer, Dorothea; Würstlein, Rachel; Culemann, Ralph; Eulenburg, Christine; Adams, Jascha; Nitzsche, Henrik; Prange, Anna; Kümmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Potenberg, Jochem; von Schumann, Raquel; Aktas, Bahriye; Kolberg-Liedtke, Cornelia; Harbeck, Nadia; Kuhl, Christiane K; Nitz, Ulrike.
In: BREAST CANCER RES, Vol. 23, No. 1, 36, 18.03.2021.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
AU - Graeser, Monika
AU - Schrading, Simone
AU - Gluz, Oleg
AU - Strobel, Kevin
AU - Herzog, Christopher
AU - Umutlu, Lale
AU - Frydrychowicz, Alex
AU - Rjosk-Dendorfer, Dorothea
AU - Würstlein, Rachel
AU - Culemann, Ralph
AU - Eulenburg, Christine
AU - Adams, Jascha
AU - Nitzsche, Henrik
AU - Prange, Anna
AU - Kümmel, Sherko
AU - Grischke, Eva-Maria
AU - Forstbauer, Helmut
AU - Braun, Michael
AU - Potenberg, Jochem
AU - von Schumann, Raquel
AU - Aktas, Bahriye
AU - Kolberg-Liedtke, Cornelia
AU - Harbeck, Nadia
AU - Kuhl, Christiane K
AU - Nitz, Ulrike
PY - 2021/3/18
Y1 - 2021/3/18
N2 - BACKGROUND: Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.METHODS: Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.RESULTS: A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.CONCLUSIONS: In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.TRIAL REGISTRATION: Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).
AB - BACKGROUND: Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.METHODS: Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.RESULTS: A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.CONCLUSIONS: In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.TRIAL REGISTRATION: Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).
KW - Adult
KW - Aged
KW - Breast Neoplasms/diagnostic imaging
KW - Female
KW - Humans
KW - Magnetic Resonance Imaging
KW - Middle Aged
KW - Neoadjuvant Therapy
KW - Neoplasm, Residual
KW - Predictive Value of Tests
KW - Receptor, ErbB-2/metabolism
KW - Receptors, Estrogen/metabolism
KW - Receptors, Progesterone/metabolism
KW - Tumor Burden
KW - Ultrasonography, Mammary
U2 - 10.1186/s13058-021-01413-y
DO - 10.1186/s13058-021-01413-y
M3 - SCORING: Journal article
C2 - 33736679
VL - 23
JO - BREAST CANCER RES
JF - BREAST CANCER RES
SN - 1465-5411
IS - 1
M1 - 36
ER -